DW

Donald Willard Weaver

Active Director Director DIN 05252976
DIN 05252976 First appointment Apr 2012 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2012
Shareholding value β€’β€’β€’β€’ Premium profile

About Donald Willard Weaver

Data last updated:

Donald Willard Weaver is a Director at Virocan Therapeutics Private Limited (since 2012). The company operates in Chemicals.

DIN 05252976
Primary Designation Director
Industry Chemicals
First Appointment 16 Apr 2012
Oldest Company Age 21 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Virocan Therapeutics Private Limited U24239AP2005PTC047169
Director16 Apr 20122005Active

Board colleagues of Donald Willard Weaver

Directorship timeline

Open interactive timeline →
Virocan Therapeutics Private Limited
Premium access

Shareholding and investment profile for Donald Willard Weaver

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Donald Willard Weaver

Donald Willard Weaver currently holds 1 directorship: Virocan Therapeutics Private Limited (Director, since 16 Apr 2012).

Donald Willard Weaver was first appointed on 16 Apr 2012 as Director at Virocan Therapeutics Private Limited.

The current boards of Donald Willard Weaver's companies include Jose Edson Silva Pontes (Virocan Therapeutics Private Limited), Rajesh Dachepalli (Virocan Therapeutics Private Limited), Sreenivasa Rao Batchu (Virocan Therapeutics Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available